RT Journal Article
SR Electronic
T1 Association of pharmacological biomarkers with treatment response and long-term disability in patients with psoriatic arthritis: results from the Outcomes of Treatment in Psoriatic Arthritis Study Syndicate
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP jrheum.190253
DO 10.3899/jrheum.190253
A1 Meghna Jani
A1 Hector Chinoy
A1 Anne Barton
YR 2019
UL http://www.jrheum.org/content/early/2019/07/23/jrheum.190253.abstract
AB Objective To identify (a)whether TNFi-drug levels/anti-drug antibodies (ADAbs) are associated with treatment response and disability in psoriatic arthritis (PsA) patients (b)factors associated with TNFidrug levels. Methods Patients were recruited from a national multi-centre prospective cohort with longitudinal serum samples and disease-activity scores/Health assessment Questionnaire(HAQ) measurement over 12-months. Results Adalimumab-drug levels were significantly associated with ΔDAS28 [β=0.055 (95%CI: 0.011, 0.099) p=0.014] and inversely with HAQ over 12-months [β=-0.022 (95%CI: -0.043, -0.00063]. Factors significantly associated with adalimumab drug levels were ADAb levels and body mass index. Conclusion Drug-level testing in adalimumab-initiated PsA patients may be useful in determining treatment response/disability over 12-months.